Analyst Ratings and Price Objectives for Aardvark Therapeutics
1 report, 1 independent
Updated Oct 19
AI-generated briefing. Brind wrote this from the reports listed below and has updated it as the story developed. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $6.00 price objective for Aardvark Therapeutics on September 24. More recently, HC Wainwright reduced its target price for Aardvark Therapeutics from $6.00 to $4.00, maintaining a neutral rating.
From dailypolitical.com
Why it matters
Changes in analyst price objectives and ratings for Aardvark Therapeutics could influence investor demand and the stock's price.
From dailypolitical.com
Who's involved
- Royal Bank of CanadaIssued a price objective and rating on Aardvark Therapeutics
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Royal Bank of CanadaSpeculative
Issuing a price objective might affect the peripheral business of the financial institution
Keep exploring
The entities involved
-
Royal Bank of Canada
financial institution in Canada
Related events
- Royal Bank of Canada trimmed its price target for Exelixis in a research report.
- Royal Bank of Canada reduced its target price for Tenet Healthcare.
- Royal Bank of Canada lifted its target price for Aurinia Pharmaceuticals Inc. on October 9, 2026.
- Royal Bank of Canada decreased its price target for BOK Financial on October 17, 2026.
- Financial firms, including RBC, TD Cowen, Leerink Partners, and Morgan Stanley, raised price targets and provided coverage for Vertex Pharmaceuticals.